Top 10 Integrated Utility Companies To Own For 2014

"If there must be trouble, let it be in my day so that my child may have peace" - Thomas Paine.

As rightly stated by Mr Paine (a famous English-American political activist, author, political theorist and revolutionary), this is what every parent wishes for. As a parent, you not only want your child to have a sound education, but also celebrations on important occasions for your little one, not to mention a grand wedding. But in order to fulfil these desires, it is imperative that you follow the right approach towards planning for your financial goals .

While planning for your child's needs, it always pays to start early. This is because if you start saving and invest early, it will give you a larger time horizon to meet your financial goals (such as child's education and marriage) and even build a bigger corpus.

Consider the following examples:

Example 1).Mr Shah has a 3 year old son, who is going to graduate after 15 years. Mr Shah intends that his son should pursue engineering. If the cost of graduation in today's terms is Rs 5 lakhs, then how much is Mr Shah going to need to send his son to engineering college after 15 years?

5 Best Net Payout Yield Stocks To Invest In Right Now: Dassault Systemes SA (DASTY.PK)

Dassault Systemes SA provides software solutions and consulting services. The Company�� global customer base includes companies primarily in 11 industrial sectors: automotive; industrial equipment; aerospace; consumer goods; consumer packaged goods; energy; high-tech; shipbuilding; life sciences; construction, and business services. It organizes its business and markets its products and services in two types of applications: the Product Lifecycle Management (PLM) market, to support product development, production, maintenance and lifecycle management, and the Mainstream three-dimensional (3D) market, which is primarily focused on product design. Its software applications address a range of products, from apparel, consumer goods, machine parts and semiconductors to automobiles, aircraft, ships and factories. In March 2011, the Company acquired Intercim. In April 2011, the Company acquired Enginuity PLM. On March 31, 2010, it acquired the IBM PLM. On June 8, 2010, the C ompany acquired Exalead, a French company providing Search Platforms and Search-Based Applications (SBA). In June 2010, the Company acquired Geensoft, a provider of embedded systems development solutions.

The Company has developed a software applications portfolio, organized in brands, in order to provide solutions responding to the requirements of product development: Design, Realistic Simulation, Digital Manufacturing and Production, Collaborative Innovation, and Lifelike Experiences. The Company�� principal brands include SolidWorks , CATIA, SIMULIA, DELMIA, ENOVIA and Universal Services.

SolidWorks

SolidWorks applications include 3D tools to design, manage, simulate, sustain and communicate. SolidWorks include 3D Design, Data management, Simulation and Environmental assessments. SolidWorks 3D�� include complex part and assembly modeling, production drawing creation, data management, design validation and simulation of motion, f low and structural performance, environmental impact evalu! at! ion and publishing. SolidWorks Data Management solutions enable control over all design information, eliminating concerns about version control or data loss. SolidWorks simulation technology ensures the quality and performance of the design before users commit to production. SolidWorks Sustainability technology enables users to assess the environmental impact of their design to create more sustainable products.

CATIA

CATIA is the Company�� PLM solution for 3D collaborative creation. CATIA addresses the complete product development process, from early product concept specification through product in service. CATIA V6 is designed to enable the spectrum of next generation collaborative virtual design. Its product portfolio is consists of four main domains, which include systems, shape design, mechanical design and equipment engineering. CATIA Systems captures, manages, and tracks product requirements with traceability, ensuring that early requiremen ts are met accurately all along the product development cycle. CATIA Shape provides a line of surfacing, reverse engineering, and visualization solutions to create, modify, and validate any type of complex shapes and help streamline the transition and collaboration among industrial designers. CATIA Mechanical delivers a collaborative and flexible design environment with concurrent engineering and change management through relational design. CATIA Equipment provides an integrated environment that enables the collaborative detailed design of electronic, electrical, and fluidic systems in context of a virtual product.

SIMULIA

SIMULIA provides a scalable portfolio of realistic simulation solutions designed to enable companies across a range of industries to improve product performance, reduce the number of physical prototypes and drive innovation. SIMULIA�� V6 portfolio spans include finite element analysis, multi-physics solutions, optimization analy sis, and simulation lifecycle management. Its finite e! lement! a! nalysis! software companies are able to create and test virtual prototypes of products and processes. Its multi-physics solutions enable companies to reach beyond the boundaries of a single domain. SIMULIA also provides design exploration and optimization technology, enabling designers and engineers to perform rapid trade-off studies of real-world behavior and accelerate product development. SIMULIA offers simulation lifecycle management, based upon the Company�� ENOVIA architecture offering an open collaborative platform for management of simulation data, processes and intellectual property.

DELMIA

DELMIA covers the Company�� PLM digital manufacturing solutions ranging from virtual process definition, workcell set-up, optimization, scheduling, and operation, to maintenance of real-time production systems. DELMIA V6 covers four principal domains, including Manufacturing planning, with 3D process and resource planning tools for creating and optimizing bu ild-to-order and lean production manufacturing systems; plant and resources engineering, with tools to virtually define and optimize manufacturing assets concurrently with manufacturing planning; program and control engineering, to virtually program, validate and simulate manufacturing systems for the virtual commissioning of production facilities, and control and production execution, which offers an accurate virtual production system to enable companies to track real time production activities, perform schedule changes, launch new programs and introduce model changeovers, and schedule maintenance operations.

ENOVIA

ENOVIA addresses business process needs across a broad spectrum of industries, managing simple, as well as engineered, complex products. The ENOVIA V6 products are organized by business processes, which include governance, global sourcing, global sourcing, and unified live collaboration. The Governance domain is designed to help compan ies launch enterprise new product introductions on! time and! ! on budget! . Governance includes these sub-processes: Requirements Management, Portfolio Configuration, Program Management, Decision Support Business Intelligence, and Compliance. The Global Sourcing domain allows companies to leverage supply chain capabilities throughout the product lifecycle. The IP Lifecycle domain helps eliminate costly product development errors as it is designed to enable improved cross-functional product design, manufacturing planning and performance simulation. The Unified Live Collaboration domain allows companies to deploy product lifecycle processes across the extended enterprise by providing a single, real-time view of information protocol (IP) across all business process domains, collaborative process management capabilities, and a service-oriented architecture that integrates with other enterprise system

The Company competes with Parametric Technology Corporation, ANSYS, Inc., MSC Software Corporation, Oracle Corporation, SAP AG, Siemens PLM Software, Adobe, Altair Engineering, Autonomy, Aveva, Bentley, Google, Intergraph, MathWorks, Nemetschek AG, Right Hemisphere, and Autodesk, Inc.

Advisors' Opinion:

• [By Markus Aarnio]

  Autodesk's competitors include Adobe Systems (ADBE), Dassault Systemes SA (DASTY.PK), and Parametric Technology Corporation (PMTC). Here is a table comparing these companies.

Top 10 Integrated Utility Companies To Own For 2014: Medidata Solutions Inc.(MDSO)

Medidata Solutions, Inc. provides software-as-a-service based clinical development solutions for life science organizations worldwide. Its solutions comprise software and services that allow customers to increase the value of their development programs by designing, planning, and managing key aspects of the clinical trial process, including study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding, clinical business analytics, and data flow and interoperability. The company primarily offers Medidata Rave, a comprehensive platform for capturing and managing clinical data. It also provides Medidata CTMS, a clinical trial management solution that streamlines operational workflows; Medidata Designer, a protocol development tool that enhances the efficiency of clinical trial start-up; Medidata Insights, a busi ness analytics platform; and Medidata Balance, a randomization and trial supply management solution, which streamlines the process of developing, building, and implementing subject allocation plans. In addition, the company offers Medidata Grants Manager, an application to benchmark the investigator budgets against industry data; Medidata contract research organization (CRO) Contractor, an analytical tool for CRO outsourcing, budgeting, and negotiation; and iMedidata, a hosted portal application that allows investigative sites and sponsor study teams to start trial activities. Further, it provides hosting, support, and professional services. The company serves pharmaceutical, biotechnology, and medical device companies; academic institutions; and CROs and other entities engaged in clinical trials through a direct sales force; and through relationships with CROs and other strategic partners. The company was founded in 1999 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Ben Levisohn]

  The iShares Russell 2000 ETF (IWM) has dropped 5.2% so far this year, while Mueller Industries (MLI), which has plunged 55%, Medidata Solutions (MDSO), which has plummeted 44%, Financial Engines (FNGN), which has slid 42%, and Isis Pharmaceuticals (ISIS), which has tumbled 42%, are the index’s biggest losers.

• [By Jake L'Ecuyer]

  Equities Trading DOWN
  Shares of Medidata Solutions (NASDAQ: MDSO) were 27.49 percent to $38.21 after the company reported downbeat quarterly results.

Top 10 Integrated Utility Companies To Own For 2014: Greatbatch Inc. (GB)

Greatbatch, Inc. provides technology solutions for medical and industrial applications. The company operates in two segments, Greatbatch Medical and Electrochem Solutions. The Greatbatch Medical segment designs and manufactures systems, components, and devices for the cardiac rhythm management, neuromodulation, vascular access, and orthopaedic markets. Its products include batteries, capacitors, filtered and unfiltered feedthroughs, engineered components, and enclosures used in implantable medical devices; instruments and delivery systems used in hip and knee replacement, and trauma and spine surgeries, as well as in hip, knee, and shoulder implants; and introducers, catheters, steerable sheaths, and implantable stimulation leads. This segment also offers value-added assembly and design engineering services for medical systems and devices. It serves primarily multi-national original equipment manufacturers. The Electrochem Solutions segment provides technology solutions fo r critical industrial applications, including customized battery power and wireless sensing systems. This segment?s products comprise cells, primary and rechargeable battery packs, and wireless sensors. It serves companies involved in energy, security, portable medical, and environmental monitoring markets. This segment sells its products directly to end users and original equipment manufactures. Greatbatch, Inc. sells its products primarily in the United States, Puerto Rico, the United Kingdom, Ireland, France, and Belgium. The company was founded in 1970 and is based in Clarence, New York.

Advisors' Opinion:

• [By mitu77]

  Various chip manufacturers are now focused on their flash drive storage portfolio to leverage their top and bottom lines. EMC (EMC) is one such company that is a market leader in storage solution providers with global foot prints. Not just the storage, but EMC also provides various solutions like security, big data and hybrid cloud solution. The company�� emerging business is its storage business with high end solutions and performance. The size of data has been exponentially growing and this growth has enabled companies like EMC to flourish. IDC ( Market research company) and EMC had jointly estimated global data size to be around 2,837 Exabytes (EB) in 2012, and it is estimated to reach 40,000 EB by 2020. As the digital world continues to expand it is further anticipated that by 2020, average storage requirement would be around 5200 Gigabytes (GB) per person. 1 Exabytes (EB) = 1000 Petabytes (PB) = 1 million Terabytes (TB) =1 billion Gigabytes (GB)

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Greatbatch (NYSE: GB  ) , whose recent revenue and earnings are plotted below.

Top 10 Integrated Utility Companies To Own For 2014: Navios Maritime Holdings Inc. (NM)

Navios Maritime Holdings Inc. operates as a seaborne shipping and logistics company. It focuses on the transportation and transshipment of dry bulk commodities, including iron ore, coal, fertilizers, and grains. The company controls a fleet of 31 owned vessels and 26 chartered-in vessels totaling 5.8 million dwt. Its owned fleet comprises 14 Ultra Handymax, 11 Capesize, 1 Handysize, and 3 Panamax vessels, as well as 2 Panamax vessels under construction; and chartered-in vessels consists of 8 Capesize, 11 Panamax, 1 Handysize, and 6 Ultra Handymax vessels under long-term time charters. The company also engages in port terminal, river barge, and coastal cabotage operations; and charters its vessels under medium to long-term charters to trading houses, producers, and government-owned entities. In addition, it engages in operating ports and transfer station terminals; and handles vessels, barges, and push boats, as well as operates upriver transport facilities in the Hidrovia region. Further, the company engages in the transportation and handling of liquid cargoes through the ownership, operation, and trading of tanker vessels. It has operations primarily in North America, Europe, Asia, and South America. The company is headquartered in Piraeus, Greece.

Advisors' Opinion:

• [By Nickey Friedman]

  Navios Maritime Holdings (NYSE: NM  ) has two operating segments: shipping and logistics. Analysts have already begun to raise their profit estimates for 2014, currently at $0.11 EPS up from $0.01 a week ago. Expect that number to continue to rise dramatically. Navios pays a $0.06 per share quarterly dividend and trades around 40% below its book value. It used to trade as high as $17 back in 2007.

Top 10 Integrated Utility Companies To Own For 2014: Global X China Energy ETF (CHIE)

Global X China Energy ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S-BOX China Energy Index (the Underlying Index). The Underlying Index is a free float adjusted, liquidity tested and market capitalization-weighted index that is designed to measure performance of the investable universe of companies in the Energy sector of the Chinese economy, as defined by Structured Solutions AG. Global X Management Company, LLC serves as the investment adviser to the Fund. Advisors' Opinion:

• [By pamatlarge]

  Investors looking to short a particular sector can choose from several Global X long ETFs. The Global X China Consumer ETF (CHIQ) concentrates its investments in consumer cyclical goods and consumer defense goods. The Global X China Energy ETF (CHIE) primarily holds stocks in coal, oil and utility companies. The Global X China Financials ETF (CHIX) only invests in financial services companies and real estate companies. The Global X China Industrials ETF (CHII) holds stocks in industrial companies and basic materials companies. The Global X China Materials ETF (CHIM) invests in basic materials stocks. The Global X China Technology ETF (CHIB) holds technology stocks as the core of its investments. All of these ETFs are particularly sensitive to sector downturns and general economic contractions.

Top 10 Integrated Utility Companies To Own For 2014: HomeServe PLC (HSV)

Homeserve plc is a United Kingdom-based company engaged in the provision of home emergency repairs. The Company operates in five segments: UK, USA, Domeo, Spain, and New Markets. Its products cover plumbing and drains, central heating, ventilation and air conditioning, electrics and household appliances, such as showers and boilers. The Company provides home emergency and repair services to over 4.9 million customers across businesses in the United Kingdom, the United States, France and Spain. It also has developing businesses in Italy, Germany and France. The Company�� subsidiaries include HomeServe Assistance Limited, HomeServe Enterprises Limited, HomeServe International Limited, HomeServe Membership Limited and Reparalia Direct SL. Advisors' Opinion:

• [By Sarah Jones]

  Homeserve Plc (HSV) climbed 8.1 percent to 265.6 pence. Liberum Capital said the company may attract private-equity buyers after reporting its full-year results. The company may soon complete its discussions with the financial-services regulator about inappropriate sales practices.

Top 10 Integrated Utility Companies To Own For 2014: Elan Corporation PLC (ELN)

Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Tysabri

Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.

In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.

Beta Amyloid Immunotherapies (AIP)

Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).

ELND005, an A� Aggregation Inhibitor

The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.

Neotope Biosciences Limited

Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.

Onclave Therapeutics Limited

Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.

The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.

Advisors' Opinion:

• [By WALLSTCHEATSHEET]

  Elan is a biotechnology company that is looking for ways to improve and better the lives of people with disruptive diseases. The company is now set to be bought-out by Perrigo. The stock has been rising over the last several months, and is now trading at prices not seen for five years. Over the last four quarters, investors have had mixed feelings about the company, as earnings have been mixed, while revenue figures have been improving. Relative to its peers and sector, Elan has been a year-to-date performance leader. Look for Elan to OUTPERFORM.

• [By WALLSTCHEATSHEET]

  Elan is a biotechnology company that is looking for ways to improve and better the lives of people with neurodegenerative and autoimmune diseases. The stock has struggled over the last couple of years and looks to be comfortable at these prices. Over the last four quarters, investors in the company have been disappointed as earnings have decreased while revenue figures have increased. Relative to its peers and sector, Elan has been a year-to-date performance leader. WAIT AND SEE what Elan does in coming quarters.

• [By Tim Brugger]

  After consulting with outside financial advisors, in conjunction with the Elan (NYSE: ELN  ) board of directors and executive management team, the Ireland-based biotechnology company has determined the recent $12.50-a-share buyout offer from Royalty Pharma undervalues select Elan assets by as much as $4.3 billion, the company announced Wednesday.